97,988 research outputs found
Transforming Tanzania's Monitoring and Evaluation System for Lasting Change
No full textThe Centre for Learning on Evaluation and Results for Anglophone Africa (CLEAR-AA), has played a pivotal role in reshaping Tanzania’s approach to monitoring and evaluation
(M&E). What was once a fragmented and underutilized system is now on the path to becoming robust and centralized, thanks to Tanzania’s bold reforms, political will and buy-in, and strategic partnerships with organizations like CLEAR-AA.MT202
Título: Nouvelle histoire universelle
No full textSign.: []\p2\s, (a)-(z)\p4\s, (aa)-(qq)\p4\sPort. a dos tintas con grab. xilAntepTexto a dos colLas il. son grab. calc. intercalados en el text
Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection?
No full textBackground: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Methods: Retrospective investigation including all patients with prior or present IVDU that underwent renal biopsy because of chronic kidney disease between 01.04.2002 and 31.03.2012 in the city of Frankfurt/Main, Germany.
Results: Twenty four patients with IVDU underwent renal biopsy because of progressive chronic kidney disease or proteinuria. Renal AA-amyloidosis was the predominant cause of renal failure in 50% of patients. Membranoproliferative glomerulonephritis (GN) was the second most common cause found in 21%. Patients with AA-amyloidosis were more likely to be HIV infected (67 vs.17%; p=0.036) and tended to have a higher rate of repeated systemic infections (92 vs. 50%; p=0.069). Patients with AA-amyloidosis presented with progressive renal disease and nephrotic-range proteinuria but most patients had no peripheral edema or systemic hypertension. Development of proteinuria preceded the decline of GFR for approximately 1--2 years.
Conclusions: AA-amyloidosis was the predominant cause of progressive renal disease in the last 10 years in patients with IVDU. The highest rate of AA-amyloidosis observed was seen in HIV infected patients with IVDU. We speculate that chronic HIV-infection as well as the associated immunosuppression might promote development of AA-amyloidosis by increasing frequency and duration of infections acquired by IVDU
Natural history and outcome in systemic AA amyloidosis
No full textBACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders. Little is known about the natural history of AA amyloidosis or its response to treatment.METHODS:We evaluated clinical features, organ function, and survival among 374 patients with AA amyloidosis who were followed for a median of 86 months. The SAA concentration was measured serially, and the amyloid burden was estimated with the use of whole-body serum amyloid P component scintigraphy. Therapy for inflammatory diseases was administered to suppress the production of SAA.RESULTS:Median survival after diagnosis was 133 months; renal dysfunction was the predominant disease manifestation. Mortality, amyloid burden, and renal prognosis all significantly correlated with the SAA concentration during follow-up. The risk of death was 17.7 times as high among patients with SAA concentrations in the highest eighth, or octile, (greater/equal 155 mg per liter) as among those with concentrations in the lowest octile (< 4 mg per liter); and the risk of death was four times as high in the next-to-lowest octile (4 to 9 mg per liter). The median SAA concentration during follow-up was 6 mg per liter in patients in whom renal function improved and 28 mg per liter in those in whom it deteriorated (P < 0.001). Amyloid deposits regressed in 60% of patients who had a median SAA concentration of less than 10 mg per liter, and survival among these patients was superior to survival among those in whom amyloid deposits did not regress (P=0.04).CONCLUSIONS:The effects of renal dysfunction dominate the course of AA amyloidosis, which is associated with a relatively favorable outcome in patients with SAA concentrations that remain in the low-normal range (< 4 mg per liter)
Open Access to Peer-Reviewed Research through Author/Institution Self-Archiving: Maximizing Research Impact by Maximizing Online Access
No full textAll refereed journals will soon be available online; most of them already are. This means that anyone will be able to access them from any networked desk-top. The literature will all be interconnected by citation, author, and keyword/subject links, allowing for unheard-of power and ease of access and navigability. Successive drafts of pre-refereeing preprints will be linked to the official refereed draft, as well as to any subsequent corrections, revisions, updates, comments, responses, and underlying empirical databases, all enhancing the self-correctiveness, interactivity and productivity of scholarly and scientific research and communication in remarkable new ways. New scientometric indicators of digital impact are also emerging <http://opcit.eprints.org> to chart the online course of knowledge. But there is still one last frontier to cross before science reaches the optimal and the inevitable: Just as there is no longer any need for research or researchers to be constrained by the access-blocking restrictions of paper distribution, there is no longer any need to be constrained by the impact-blocking financial fire-walls of Subscription/Site-License/Pay-Per-View (S/L/P) tolls for this give-away literature. Its author/researchers have always donated their research reports for free (and its referee/researchers have refereed for free), with the sole goal of maximizing their impact on subsequent research (by accessing the eyes and minds of fellow-researchers, present and future) and hence on society. Generic (OAi-compliant) software is now available free so that institutions can immediately create Eprint Archives in which their authors can self-archive all their refereed papers for free for all forever <http://www.eprints.org/>. These interoperable Open Archives <http://www.openarchives.org> will then be harvested into global, jointly searchable "virtual archives" (e.g., <http://arc.cs.odu.edu/>). "Scholarly Skywriting" in this PostGutenberg Galaxy will be dramatically (and measurably) more interactive and productive, spawning its own new digital metrics of productivity and impact, allowing for an online "embryology of knowledge.
Eprodisate for the treatment of renal disease in AA amyloidosis
No full textBackground: Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.
Methods: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183 patients from 27 centers to receive eprodisate or placebo for 24 months. The primary composite end point was an assessment of renal function or death. Disease was classified as worsened if any one of the following occurred: doubling of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-stage renal disease, or death.
Results: At 24 months, disease was worsened in 24 of 89 patients who received eprodisate (27%) and 38 of 94 patients given placebo (40%, P=0.06); the hazard ratio for worsening disease with eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 m2 of body-surface area per year in the eprodisate and the placebo groups, respectively (P=0.02). The drug had no significant effect on progression to end-stage renal disease (hazard ratio, 0.54; P=0.20) or risk of death (hazard ratio, 0.95; P=0.94). The incidence of adverse events was similar in the two groups.
Conclusions: Eprodisate slows the decline of renal function in AA amyloidosis
Ryhiner-Kartensammlung / 33 Nouvelle carte de l'Amerique : avec tous ses royaumes, e[s]tats, iles, ports, bayes et rivieres : dressée suivant les plus nouvelles decouvertes par les plus habiles géographes
No full textet tout nouvellement mise en lumiere par Pierre van der Aa, marchand libraireTitel- und Massstabskartusche oben link
Título: Opera omnia.
No full textSign.: ]\p4\s, *\p4\s, 2*\p8\s, 3*-10*\p4\s, A-3Z\p4\s, 4A-4G\p4\s, 4H\p3\s.Error de col., repite la numeración de las col. 1105-1106.Texto a dos col.Port. a dos tintas con grab. calc.: "J. Goerce del. V. Baptist. scul."Cada tomo con antep. y port. propia.Front. calc.: "H.V. Aa Inv., W.V. Mieris del., I. Baptist sculp :" alegórica.Las h. de grab. calc. : "Hill. vander Aa Inv. et delin. I van Vianen Sculp." escudo nobiliario ; "H. rander AA delin, D. Stoopendaal scul.", estatua de tramo ; "H. Holbeen pinxit, A. vander Eryk delin, P. van Gunst sculps", retrato de Eramo las otras dos, epitafio y medallas
Thesaurus antiquitatum romanarum : in quo continentur lectissimi quinque scriptores...
No full textEn el frontis: Petrum Van Der AA. El lugar de edición es Utrecht: en el Espasa "Ultrajectum" traject. ad RhenSign.: [*]\p6\s, 2[*]-5[*]\p4\s, 6[*]\p2\s, (a)-(b)\p4\s, A-Z\p4\s, 2A-2Z\p4\s, 3A-3R\p4\s, 3S\p3\s, A-I\p4\sPort. a dos tintas, con grab. calc.: "J. Goeree delin., J. Baptist. sculp."AntepFrontis calc.: "J. Mulder fecit"Las h. de grab. pleg. calc., son mapas, del Imperio romano de Oriente y de Occidente respectivamente, entre las col. 344-34
t2_aln_v02_aa.fasta AA alignment of T2/S-RNases
No full textt2_aln_v02_aa.fasta AA alignment of T2/S-RNase
- …
